High Pointe Capital Management’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-5,000
| Closed | -$437K | – | 87 |
|
|
2021
Q4 | $437K | Buy |
5,000
+520
| +12% | +$43.2K | 0.29% | 79 |
|
|
2021
Q3 | $366K | Hold |
4,480
| – | – | 0.29% | 80 |
|
|
2021
Q2 | $409K | Sell |
4,480
-500
| -10% | -$44.5K | 0.32% | 77 |
|
|
2021
Q1 | $426K | Buy |
4,980
+190
| +4% | +$17.1K | 0.37% | 67 |
|
|
2020
Q4 | $452K | Buy |
4,790
+800
| +20% | +$69.9K | 0.43% | 65 |
|
|
2020
Q3 | $347K | Hold |
3,990
| – | – | 0.42% | 68 |
|
|
2020
Q2 | $348K | Hold |
3,990
| – | – | 0.46% | 62 |
|
|
2020
Q1 | $329K | Buy |
3,990
+240
| +6% | +$21.4K | 0.47% | 57 |
|
|
2019
Q4 | $355K | Hold |
3,750
| – | – | 0.42% | 63 |
|
|
2019
Q3 | $326K | Hold |
3,750
| – | – | 0.45% | 67 |
|
|
2019
Q2 | $342K | Sell |
3,750
-2,276
| -38% | -$193K | 0.48% | 64 |
|
|
2019
Q1 | $519K | Sell |
6,026
-759
| -11% | -$60.9K | 0.71% | 60 |
|
|
2018
Q4 | $522K | Sell |
6,785
-313
| -4% | -$24.4K | 0.86% | 48 |
|
|
2018
Q3 | $548K | Hold |
7,098
| – | – | 0.74% | 48 |
|
|
2018
Q2 | $480K | Sell |
7,098
-156
| -2% | -$10.8K | 0.68% | 53 |
|
|
2018
Q1 | $526K | Buy |
7,254
+558
| +8% | +$42.5K | 0.72% | 55 |
|
|
2017
Q4 | $504K | Hold |
6,696
| – | – | 0.69% | 53 |
|
|
2017
Q3 | $515K | Buy |
6,696
+625
| +10% | +$47.2K | 0.75% | 53 |
|
|
2017
Q2 | $454K | Buy |
6,071
+1,808
| +42% | +$128K | 0.7% | 56 |
|
|
2017
Q1 | $284K | Hold |
4,263
| – | – | 0.45% | 67 |
|
|
2016
Q4 | $278K | Buy |
+4,263
| New | +$277K | 0.46% | 60 |
|
|
2016
Q3 | – | Sell |
-7,321
| Closed | -$541K | – | 86 |
|
|
2016
Q2 | $541K | Hold |
7,321
| – | – | 0.82% | 49 |
|
|
2016
Q1 | $475K | Sell |
7,321
-8,850
| -55% | -$602K | 0.69% | 47 |
|
|
2015
Q4 | $1.25M | Buy |
16,171
+121
| +0.8% | +$9.61K | 0.61% | 56 |
|
|
2015
Q3 | $1.32M | Buy |
16,050
+672
| +4% | +$59.8K | 0.62% | 54 |
|
|
2015
Q2 | $1.35M | Hold |
15,378
| – | – | 0.48% | 92 |
|
|
2015
Q1 | $1.36M | Sell |
15,378
-7,176
| -32% | -$637K | 0.49% | 87 |
|
|
2014
Q4 | $1.87M | Sell |
22,554
-949
| -4% | -$78.7K | 0.83% | 49 |
|
|
2014
Q3 | $1.98M | Buy |
23,503
+3,460
| +17% | +$280K | 0.86% | 40 |
|
|
2014
Q2 | $1.63M | Buy |
20,043
+201
| +1% | +$15.8K | 0.59% | 89 |
|
|
2014
Q1 | $1.51M | Buy |
19,842
+5,267
| +36% | +$384K | 0.58% | 91 |
|
|
2013
Q4 | $1.05M | Buy |
14,575
+8,549
| +142% | +$594K | 0.41% | 101 |
|
|
2013
Q3 | $414K | Buy |
6,026
+111
| +2% | +$7.34K | 0.17% | 116 |
|
|
2013
Q2 | $375K | Buy |
+5,915
| New | +$385K | 0.16% | 116 |
|
Other funds holding NVS
High Pointe Capital Management's NVS Position: Q1 2022 in Review
High Pointe Capital Management sold out of Novartis (NVS) in Q1 2022, closing a stake of 5,000 shares — an estimated $437K sold.
High Pointe Capital Management first reported a position in NVS in Q2 2013 and held it in 34 quarters. The position peaked at $1.98M in Q3 2014. 1,136 funds tracked by Wall St. Rank hold NVS as of Q1 2022.
- High Pointe Capital Management reported no remaining Novartis position as of Q1 2022 after selling out during the quarter.
- High Pointe Capital Management sold 5,000 Novartis shares in Q1 2022, an estimated $437K.
- High Pointe Capital Management first reported a position in Novartis in Q2 2013 and held it in 34 quarters.
- High Pointe Capital Management's Novartis position peaked at $1.98M in Q3 2014.
- 1,136 funds tracked by Wall St. Rank held Novartis as of Q1 2022.
Based on High Pointe Capital Management's 13F filing for Q1 2022, filed 10 May 2022.